Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide And Tirzepatide

AMPLIFY-1

Eli Lilly · Phase 3 · Not yet recruiting · Enrollment 2115

NCT07881432

ArmPopulationDoseWeeksEstimandWeight change
EloraTZP Dose 1Obesity or overweightn/rn/rn/rn/r
EloraTZP Dose 2Obesity or overweightn/rn/rn/rn/r
EloraTZP Dose 3Obesity or overweightn/rn/rn/rn/r
EloraTZP Dose 4Obesity or overweightn/rn/rn/rn/r
EloraTZP Dose 5Obesity or overweightn/rn/rn/rn/r
TirzepatideObesity or overweightn/rn/rn/rn/r
EloralintideObesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r